Mizuho Securities Remains Bullish on Horizon Pharma (HZNP); Says Subpoena Appears Benign
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Horizon Pharma plc Recognizes Rare Disease Community on the "Rarest Day of the Year"
February 29, 2016 7:30 AM ESTDUBLIN, IRELAND -- (Marketwired) -- 02/29/16 -- Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today joins rare disease patient advocates worldwide in supporting the ninth annual international Rare Disease Day.
Organized annually on the last day of February by the European Organization for Rare Diseases (EURORDIS) and supported in the United... More
Horizon Pharma plc Announces Record Fourth-Quarter and Full-Year 2015 Financial Results and Confirms Full-Year 2016 Sales and Adjusted EBITDA Guidance
February 29, 2016 7:00 AM ESTDUBLIN, IRELAND -- (Marketwired) -- 02/29/16 -- Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced its fourth-quarter and full-year 2015 financial results today and confirmed its full-year 2016 net sales and adjusted EBITDA guidance.
Financial Highlights (in millions except for per share amounts and % % percentages) Q4 15 Q4 14 Change FY 15 FY 14 Change ------- ------- ------ ------- ------- ------ Net sales $ 244.5 $ 103.8 135 $ 757.0 $ 297.0 155 Net income (loss) 24.0 (31.6) NM 39.5 (263.6) NM Adjusted non-GAAP net income 102.4 25.9 295 305.9 72.1 324 Adjusted EBITDA 122.5 34.8 252 362.1 87.1 316 Earnings (loss) per share - basic $ 0.15 $ (0.27) NM... More
